Literature DB >> 16127061

In vitro and in vivo effects of soluble, monovalent globotriose on bacterial attachment and colonization.

James L Leach1, Stacey A Garber, Andrea A Marcon, Pedro A Prieto.   

Abstract

Epithelial cells lining the urinary tract are rich in globo series glycolipids, structurally defined by a Galalpha1,4Gal motif in the oligosaccharide moiety of this glycolipid family. This Galalpha1,4Gal motif is the attachment target for the P-fimbrial adhesin of uropathogenic Escherichia coli. We investigated the ability of a trisaccharide analog of this core motif, globotriose (Galalpha1,4Galbeta1,4Glc), to interfere with uropathogen attachment and colonization in vitro and in vivo. We assessed the ability of globotriose to inhibit and reverse the binding and agglutination of a P-fimbriated strain of E. coli (JR1) using human erythrocytes and immortalized human colonic epithelial cells as targets. Globotriose (5 mg/ml) completely inhibited and reversed cell agglutination and caused a 10- to 100-fold reduction in JR1 binding to target cells, as determined by flow cytometry. In preparation for an in vivo efficacy study, we investigated the distribution and pharmacokinetics of globotriose in the BALB/c mouse. Globotriose was administered via the tail vein, targeting an instantaneous plasma concentration of 5 mg/ml, and in a different experiment, animals were gavaged at 10 times the intravenous (i.v.) dose. Globotriose was rapidly cleared from plasma (half-life [t1/2], 6 min) and slowly excreted via the kidney (t1/2, 4 h). Urine levels of >5 mg/ml were maintained from 4 to 12 h after the i.v. bolus dose, which resulted in a 1-log reduction in established bladder colonization by JR1. These results suggest that free, soluble globotriose is a feasible alternative therapy for urinary tract infections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16127061      PMCID: PMC1195436          DOI: 10.1128/AAC.49.9.3842-3846.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands.

Authors:  P I Kitov; J M Sadowska; G Mulvey; G D Armstrong; H Ling; N S Pannu; R J Read; D R Bundle
Journal:  Nature       Date:  2000-02-10       Impact factor: 49.962

Review 2.  Pilus and nonpilus bacterial adhesins: assembly and function in cell recognition.

Authors:  S J Hultgren; S Abraham; M Caparon; P Falk; J W St Geme; S Normark
Journal:  Cell       Date:  1993-06-04       Impact factor: 41.582

3.  Prevention of pyelonephritis by immunization with P-fimbriae.

Authors:  J A Roberts; K Hardaway; B Kaack; E N Fussell; G Baskin
Journal:  J Urol       Date:  1984-03       Impact factor: 7.450

4.  Virulence of Escherichia coli in relation to host factors in women with symptomatic urinary tract infection.

Authors:  T Sandberg; B Kaijser; G Lidin-Janson; K Lincoln; F Orskov; I Orskov; E Stokland; C Svanborg-Edén
Journal:  J Clin Microbiol       Date:  1988-08       Impact factor: 5.948

Review 5.  Safe as mother's milk: carbohydrates as future anti-adhesion drugs for bacterial diseases.

Authors:  N Sharon; I Ofek
Journal:  Glycoconj J       Date:  2000 Jul-Sep       Impact factor: 2.916

6.  Inhibition of experimental ascending urinary tract infection by an epithelial cell-surface receptor analogue.

Authors:  C S Edén; R Freter; L Hagberg; R Hull; S Hull; H Leffler; G Schoolnik
Journal:  Nature       Date:  1982-08-05       Impact factor: 49.962

7.  Large-scale production of UDP-galactose and globotriose by coupling metabolically engineered bacteria.

Authors:  S Koizumi; T Endo; K Tabata; A Ozaki
Journal:  Nat Biotechnol       Date:  1998-09       Impact factor: 54.908

8.  Carbohydrates in cell recognition.

Authors:  N Sharon; H Lis
Journal:  Sci Am       Date:  1993-01       Impact factor: 2.142

9.  Host-specificity of uropathogenic Escherichia coli depends on differences in binding specificity to Gal alpha 1-4Gal-containing isoreceptors.

Authors:  N Strömberg; B I Marklund; B Lund; D Ilver; A Hamers; W Gaastra; K A Karlsson; S Normark
Journal:  EMBO J       Date:  1990-06       Impact factor: 11.598

10.  A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans.

Authors:  A W Paton; R Morona; J C Paton
Journal:  Nat Med       Date:  2000-03       Impact factor: 53.440

View more
  2 in total

Review 1.  Clinical applications of bioactive milk components.

Authors:  David R Hill; David S Newburg
Journal:  Nutr Rev       Date:  2015-07       Impact factor: 7.110

2.  TLR4 facilitates translocation of bacteria across renal collecting duct cells.

Authors:  Cécilia Chassin; Sophie Vimont; Françoise Cluzeaud; Marcelle Bens; Jean-Michel Goujon; Béatrice Fernandez; Alexandre Hertig; Eric Rondeau; Guillaume Arlet; Mathias W Hornef; Alain Vandewalle
Journal:  J Am Soc Nephrol       Date:  2008-08-27       Impact factor: 10.121

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.